Table 1. The expression of SLC2A1 in each clinical subgroup of the TCGA-LUAD dataset.
| Characteristic | Low SLC2A1 expression (n=267) | High SLC2A1 expression (n=268) | P value |
|---|---|---|---|
| T stage, n (%) | <0.001 | ||
| T1 | 108 (20.3) | 67 (12.6) | |
| T2 | 133 (25.0) | 156 (29.3) | |
| T3 | 14 (2.6) | 35 (6.6) | |
| T4 | 10 (1.9) | 9 (1.7) | |
| N stage, n (%) | 0.015 | ||
| N0 | 186 (35.8) | 162 (31.2) | |
| N1 | 38 (7.3) | 57 (11.0) | |
| N2 | 30 (5.8) | 44 (8.5) | |
| N3 | 0 (0) | 2 (0.4) | |
| M stage, n (%) | 0.225 | ||
| M0 | 183 (47.4) | 178 (46.1) | |
| M1 | 9 (2.3) | 16 (4.1) | |
| Pathologic stage, n (%) | 0.002 | ||
| Stage I | 168 (31.9) | 126 (23.9) | |
| Stage II | 51 (9.7) | 72 (13.7) | |
| Stage III | 33 (6.3) | 51 (9.7) | |
| Stage IV | 10 (1.9) | 16 (3.0) | |
| Gender, n (%) | 0.004 | ||
| Female | 160 (29.9) | 126 (23.6) | |
| Male | 107 (20.0) | 142 (26.5) | |
| OS event, n (%) | <0.001 | ||
| Alive | 193 (36.1) | 150 (28.0) | |
| Dead | 74 (13.8) | 118 (22.1) | |
| DSS event, n (%) | <0.001 | ||
| Alive | 208 (41.7) | 171 (34.3) | |
| Dead | 43 (8.6) | 77 (15.4) | |
| PFS event, n (%) | 0.007 | ||
| Alive | 170 (31.8) | 139 (26.0) | |
| Dead | 97 (18.1) | 129 (24.1) | |
| Age, median [IQR] | 67 [60, 73] | 65 [58, 72] | 0.135 |
T, tumor; N, node; M, metastasis; TCGA, The Cancer Genome Atlas; LUAD, lung adenocarcinoma; OS, overall survival; DSS, disease specific survival; PFS, progression free survival; IQR, interquartile range.